Key result
Acute kidney injury occurred in 69% of head and neck cancer patients undergoing high-dose cisplatin chemoradiation, with hypertension and nausea/vomiting identified as significant risk factors.
Why the study?
Concurrent chemoradiation with high-dose cisplatin for locally advanced squamous cell carcinoma of the head and neck causes significant toxicities, including acute kidney injury. The study aimed to assess the incidence of acute kidney injury, identify risk factors, and describe its impact on long-term renal function and outcomes.
What is the incidence and what are the risk factors for acute kidney injury in patients with LA-SCCHN treated with concurrent chemoradiation with high-dose cisplatin?
Cohort (n=124)
No
What is the incidence and what are the risk factors for acute kidney injury in patients with LA-SCCHN treated with concurrent chemoradiation with high-dose cisplatin?
High-dose cisplatin-based chemoradiation for head and neck cancer causes acute kidney injury in 69% of patients, with hypertension and chemotherapy-induced nausea and vomiting being significant risk factors.
High AKI incidence during cisplatin chemoradiation supports vigilant renal monitoring; leaves open whether hypertension or antiemetic control reduces risk.
No takes yet. Share an insight, caveat, or question.
Vorst et al. (2019) conducted a cohort in Locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) (n=124). High-dose cisplatin-based chemoradiation was evaluated on Incidence of Acute Kidney Injury (AKI) according to KDIGO criteria. Acute kidney injury occurred in 69% of head and neck cancer patients undergoing high-dose cisplatin chemoradiation, with hypertension and nausea/vomiting identified as significant risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: